نتایج جستجو برای: ژن cyp2c9

تعداد نتایج: 17690  

2005
Soo-Youn Lee June Soo Kim Jong-Won Kim

We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient heterozygous for the CYP2C9*3 allele. A 30-year-old woman with an artificial cardiac pacemaker was taking warfarin to prevent thromboembolism. This patient had an extremely elevated international normalized ratio (INR) of prothrombin time (PT) following standard doses of warfarin and experienced diff...

Journal: :Basic & clinical pharmacology & toxicology 2009
Eugen Muschler Jawahar Lal Alexander Jetter Anke Rattay Ulrich Zanger Gregor Zadoyan Uwe Fuhr Julia Kirchheiner

The cytochrome P450 enzyme CYP2C8 appears to have a major role in pioglitazone metabolism. The present study was conducted to further clarify the role of individual CYPs and of the CYP2C8/9 polymorphisms in the primary metabolism of pioglitazone in vitro. Pioglitazone (2-400 microM) was incubated with isolated cytochrome P450 enzymes or human liver microsomes, some of them carrying either the C...

2016
Loulia Akram Bader Hazem Elewa

BACKGROUND Warfarin is the most commonly used oral anticoagulant for the treatment and prevention of thromboembolic disorders. Pharmacogenomics studies have shown that variants in CYP2C9 and VKORC1 genes are strongly and consistently associated with warfarin dose variability. Although different populations from the Middle East and North Africa (MENA) region may share the same ancestry, it is st...

Journal: :The Journal of pharmacology and experimental therapeutics 2002
Judy L Raucy Lisa Mueller Kui Duan Scott W Allen Stephen Strom Jerome M Lasker

Although CYP2C8, CYP2C9, and CYP2C19 play an important role in drug biotransformation, factors influencing the expression and activity of these CYP2C P450s in human liver remain largely undefined. We used primary cultures of human hepatocytes from 15 subjects to assess the inducibility of CYP2C enzyme expression by prototypical inducer agents, including rifampicin, dexamethasone, and phenobarbi...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2009
Murali Subramanian Michael Low Charles W Locuson Timothy S Tracy

Cytochrome P450 (P450) protein-protein interactions have been observed with various in vitro systems. It is interesting to note that these interactions seem to be isoform-dependent, with some combinations producing no effect and others producing increased or decreased catalytic activity. With some exceptions, most of the work to date has involved P450s from rabbit, rat, and other animal species...

Journal: :Blood 2005
Elizabeth A Sconce Tayyaba I Khan Hilary A Wynne Peter Avery Louise Monkhouse Barry P King Peter Wood Patrick Kesteven Ann K Daly Farhad Kamali

Current dosing algorithms do not account for genetic and environmental factors for warfarin dose determinations. This study investigated the contribution of age, CYP2C9 and VKORC1 genotype, and body size to warfarin-dose requirements. Studied were 297 patients with stable anticoagulation with a target international normalized ratio (INR) of 2.0 to 3.0. Genetic analyses for CYP2C9 (*2 and *3 all...

Journal: :Blood 2009
Chun Li Ute I Schwarz Marylyn D Ritchie Dan M Roden C Michael Stein Daniel Kurnik

Genetic variants in CYP2C9 and VKORC1 strongly affect steady-state warfarin dose. However, these variants also affect early international normalized ratio (INR) values during warfarin initiation. We examined whether CYP2C9/VKORC1 genotypes provide information about warfarin sensitivity additional to that provided by early INR responses. In 214 patients starting warfarin with INR-guided dose adj...

Journal: :Clinical chemistry 2009
Tohru Aomori Koujirou Yamamoto Atsuko Oguchi-Katayama Yuki Kawai Takefumi Ishidao Yasumasa Mitani Yasushi Kogo Alexander Lezhava Yukiyoshi Fujita Kyoko Obayashi Katsunori Nakamura Hugo Kohnke Mia Wadelius Lena Ekström Cristine Skogastierna Anders Rane Masahiko Kurabayashi Masami Murakami Paul E Cizdziel Yoshihide Hayashizaki Ryuya Horiuchi

BACKGROUND Polymorphisms of the CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) gene (CYP2C9*2, CYP2C9*3) and the VKORC1 (vitamin K epoxide reductase complex, subunit 1) gene (-1639G>A) greatly impact the maintenance dose for the drug warfarin. Prescreening patients for their genotypes before prescribing the drug facilitates a faster individualized determination of the proper mai...

A high prevalence of genetic polymorphisms increases sensitivity to warfarin therapy. In this study, we investigated 47 patients with effective long-term therapy by warfarin well-controlled by monitoring of International Normalised Ratio (INR). All patients were tested for gene polymorphisms VKORC1, CYP2C9*C2, and CYP2C9*C3, which were used for a dose calculation employing a program www.Warfari...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید